FEDERAL COURT OF AUSTRALIA
Gensco Laboratories, LLC v Care A2 Plus Pty Ltd (receiver appointed) (No 2) [2024] FCA 23
File number(s): NSD 560 of 2023 Judgment of: HALLEY J Date of judgment: 22 January 2024 Catchwords: COSTS – interlocutory application for security for costs of and incidental to the statement of cross claim (Cross Claim) by applicants/cross-respondents (application) – whether there is reason to believe that the first respondent could not meet an adverse costs order – whether Cross Claim is purely defensive – quantum of security of costs to be provided – security to be provided in tranches – orders made substantially in the form sought by the applicants/cross-respondents Legislation: Corporations Act 2001 (Cth) ss 56, 1335
Competition and Consumer Act 2010 (Cth), Sch 2 (Australian Consumer Law) s 18
Federal Court of Australia Act 1976 (Cth) s 56
Federal Court Rules 2011 (Cth) r 19.01
Cases cited: A1 for Maintenance Pty Ltd v Lehal Pty Ltd [2018] FCA 1476
Allstate Life Insurance Co v Australia & New Zealand Banking Group Ltd (No 19) (1995) 134 ALR 187
Austcorp Project Number 20 Pty Ltd v LM Investment Management Ltd (in liq) [2014] FCA 1371
Bevwizz Group Pty Ltd v Transport Solutions Pty Ltd [2008] NSWSC 1399
Classic Ceramic Importers Pty Ltd v Ceramica Antiga SA (1994) 13 ACSR 263
Eastern Pearl Corporation v Groundhog Sales & Rentals Pty Ltd [2011] FCA 411
Energy City Qatar Holding Company v Hub Street Equipment Pty Ltd [2020] FCA 1033
Forest Carbon Methodology Pty Ltd v Schultz [2023] FCA 943
Health Information Pharmacy Franchising Pty Ltd v Khoo [2010] FCA 438
HP Mercantile Pty Ltd v Dierickx [2013] NSWCA 87
Hurworth Nominees Pty Ltd v ANZ Banking Group Ltd [2005] NSWSC 1360
Interwest Ltd v Tricontinental Corporation Ltd (1991) 9 ACLC 1218
John Arnold’s Surf Shop (in liquidation) v Heller Factors Pty Ltd (1979) 22 SASR 20
Meni’s Tailoring & Alterations Pty Limited v Jeanswest Corporation Pty Ltd [2003] FCA 1108
Nine Films & Television Pty Ltd v Ninox Television Limited (2005) 146 FCR 144; [2005] FCA 735
Sergienko v AXL Financial Pty Ltd [2019] NSWSC 1611
Sydmar Pty Ltd v Statewise Developments Pty Ltd (1987) 73 ALR 289
Toolgen Incorporated v Fisher [2019] FCA 2158
Visco v Minter [1969] 2 All ER 714
Division: General Division Registry: New South Wales National Practice Area: Commercial and Corporations Sub-area: Commercial Contracts, Banking, Finance and Insurance Number of paragraphs: 75 Date of hearing: 19 December 2023 Counsel for the Applicants: Ms E Bathurst Solicitor for the Applicants: King & Wood Mallesons Counsel for the First and Third Respondents: Mr G Drew Solicitor for the First and Third Respondents: Piper Alderman Counsel for the Second and Fourth Respondents: The second and fourth respondents did not appear ORDERS
NSD 560 of 2023 BETWEEN: GENSCO LABORATORIES, LLC (DOING BUSINESS AS GENSCO PHARMA)
First Applicant
GENSCO…
Keep reading for free
Create a free CaseChat account to read Gensco Laboratories, LLC v Care A2 Plus Pty Ltd (receiver ap... and more:
- Read every judgment in full
- Ask AI and get answers linked to paragraphs
- See how each paragraph was cited in later cases
- Download judgments as PDF or Word
One click creates your free account or signs you in.
By continuing you agree to the Terms and Privacy Policy.
- Case
- [2024] FCA 23
- Decision Date
CaseChat Overview and Summary
The court found that there was reason to believe Care A2 could not meet an adverse costs order, primarily due to the unexplained appointment of a receiver since December 2022 and the registration of security interests over Care A2's assets without clear explanations. These factors, coupled with Care A2's refusal to address Gensco's concerns about its financial position, led the court to conclude that Care A2 was likely unable to meet a costs order. Additionally, the court determined that the cross claim was not purely defensive, as it involved substantive allegations against Gensco and its officers.
The court ordered that Care A2 must provide security for Gensco's costs in relation to the cross claim in the amount of $675,859.05. This security is to be paid in an initial tranche of $50,000 by 19 February 2024, with subsequent tranches to be agreed upon by the parties or determined by the court. The cross claim will be stayed until the initial security is provided and will be dismissed if not met by 7 March 2024, with Care A2 liable for Gensco's costs.
Orders
Orders of the court
1. Pursuant to r 19.01(1)(a) of the Federal Court Rules 2011 (Cth) (Rules), the first respondent/cross-claimant is to provide security for the applicants’/cross-respondents’ costs of and incidental to the statement of cross claim filed on 19 September 2023 (Cross Claim), in the amount of $675,859.05, to be paid into Court by way of:
(a) an initial tranche of $50,000 by 4.30 pm on Monday, 19 February 2024; and
(b) subsequent tranches of security, to be agreed between the parties, or in the absence of agreement, in a manner to be determined by the Court at the case management hearing at 9.30 am on Friday, 1 March 2024.
2. Pursuant to r 19.01(1)(b) of the Rules, the Cross Claim be stayed pending provision of the initial tranche of security in the amount of $50,000 by the first respondent/cross-claimant pursuant to Order 1 of these orders.
3. If the initial tranche of security in the amount of $50,000 is not provided in accordance with Order 1 of these orders by Thursday, 7 March 2024, the Cross Claim be dismissed as against the applicants/cross-respondents, and the first respondent/cross-claimant is to pay the applicants’/cross-respondents’ costs of and incidental to the Cross Claim as agreed or taxed.
Note: Entry of orders is dealt with in Rule 39.32 of the Federal Court Rules 2011.
Background
Background to the litigation
Decision
Reasons for decision
1. Is there reason to believe that the first respondent could not meet an adverse costs order?
2. Is the Cross Claim purely defensive?
3. What is the appropriate quantum of security for costs to be provided by the first respondent with respect to the Cross Claim?
Held
1. There is reason to believe that the first respondent could not meet an adverse costs order.
2. The Cross Claim is not purely defensive.
3. The appropriate quantum of security for costs to be provided by the first respondent with respect to the Cross Claim is $675,859.05.
Ratio Decidendi
Legal Principle Established
Care A2, therefore, submits that the Court’s jurisdiction to order security is not engaged and, accordingly, there is no compelling reason for Care A2 to have adduced any evidence as to its financial position.C.3. Consideration In my view, Gensco has established that there is reason to believe that Care A2 may not be able to meet an adverse costs order, for the following reasons. First, the appointment of a receiver to Care A2 since 2 December 2022 provides a credible reason, in the absence of any evidence explaining the extent, nature or scope of the appointment, that Care A2 may not be able to meet an adverse costs order. An Australian Securities and Investments Commission (ASIC) company search extracted on 10 October 2023, annexed to Ms Madar’s first affidavit, provides the following descriptions of external administration documents (a) “notice by external administrator/controller-appoint/cease appointment by receiver” lodged on 2 December 2022, and (b) “notification of an appointment of a receiver” lodged on 14 December 2022. Although the first description appears to be generic on its face, when read in the context of the second description, it is confirmation of the appointment of the receiver on 2 December 2022. A further ASIC company search extracted on 23 November 2023, annexed to Ms Madar’s second affidavit, confirms that Care A2’s status remains “under external administration and/or controller appointed”. Care A2 made forensic decisions not to lead any evidence explaining the circumstances in which the receiver was appointed and objected to the admissibility of any evidence relied upon by Gensco with respect to the receivership on hearsay grounds. I do not accept the submission made by Care A2, that an unexplained appointment of a receiver over all the assets of a corporation does not give rise to any inference that the corporation may not be able to meet an adverse costs order. Second, and relatedly, the unexplained registration of security interests over the assets of Care A2, by GI 305 and Fishbank, at least as to the quantum of the amounts secured, provides further reason to believe that Care A2 may not be able to meet an adverse costs order. Collateral class descriptions in relation to the relevant security interests are outlined in the PPSR Summary, which is annexed to Ms Madar’s first affidavit. The PPSR Summary describes the security interest of GI 305 over the assets of Care A2 using the description of “all present and after-acquired property – no exceptions”. It further describes the various security interests of Fishbank with reference to the following collateral class descriptions (a) “all present and after-acquired property – no exceptions”, (b) “any and all goods the subject of the general security agreement, or any other financing arrangement, between the secured party and the grantor”, and (c) a list of specific plant and equipment. Third, I am satisfied that the otherwise unexplained appointment of a receiver to Care A2 does give rise to an evidentiary onus on the part of Care A2 to establish that it would be able to meet an adverse costs order. Further, the communications annexed to Ms Madar’s affidavit make clear that Gensco raised serious and substantive concerns about the ability of Care A2 to meet any adverse costs order with respect to the Cross Claim and each of those requests were refused by Care A2. The absence of any explanation of the extent, nature or scope of the appointment of the receiver, together with the absence of any evidence of the amounts secured by relevant security interests identified in the PPSR Summary, allows me to more readily draw an inference, in all the circumstances, that there is reason to believe that Care A2 would not be able to meet an adverse costs order. The amount sought by Gensco as security for its costs is substantial, it could not readily be inferred in the absence of any explanation of Care A2’s financial position that Care A2 could meet an adverse cost order.D. IS THE CROSS CLAIM PURELY DEFENSIVE?D.1. Legal principles